Tiziana Life Sciences (LON:TILS) Hits New 52-Week Low at $30.00

Tiziana Life Sciences PLC (LON:TILS)’s stock price hit a new 52-week low on Thursday . The stock traded as low as GBX 30 ($0.39) and last traded at GBX 40 ($0.52), with a volume of 12966 shares changing hands. The stock had previously closed at GBX 40 ($0.52).

The firm has a 50 day moving average of GBX 51.23 and a two-hundred day moving average of GBX 58.36. The stock has a market cap of $54.59 million and a P/E ratio of -8.70. The company has a debt-to-equity ratio of 59.12, a quick ratio of 0.31 and a current ratio of 0.32.

About Tiziana Life Sciences (LON:TILS)

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma.

Featured Article: Holder of Record

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.